This brand name is authorized in Poland
The drug LAPIMYL contains one active pharmaceutical ingredient (API):
|
1
Lacidipine
UNII 260080034N - LACIDIPINE
|
|
Lacidipine is a specific and potent calcium antagonist with a predominant selectivity for calcium channels in the vascular smooth muscle. Its main action is to dilate peripheral arterioles, reducing peripheral vascular resistance and lowering blood pressure. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C08CA09 | Lacidipine | C Cardiovascular system → C08 Calcium channel blockers → C08C Selective calcium channel blockers with mainly vascular effects → C08CA Dihydropyridine derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100360333, 100360340, 100360356 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
